Finerenone Provides CV, Renal Benefits in Diabetes Across CKD Spectrum
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Myocardial Infarction
Fixed-Dose Combination Therapies Reduce Cardiovascular Risk
Fixed-dose combo with BP-lowering meds, statin, and aspirin yields largest reduction in cardiovascular risk
New Drug Product: Kerendia
This slideshow show drug information for Kerendia. Click here for the complete Kerendia monograph.
Risk for Myocarditis in Young Who Get Moderna Shots May Be Greater Than Thought
However, health officials emphasize that COVID-19 puts someone at much greater risk for heart inflammation than getting the vaccine does
Review Compiles Myocarditis Cases Associated With COVID-19
COVID-19-related myocarditis profiled from 42 cases reported in articles published from December 2019 through January 5, 2021
ACIP: Benefits of mRNA COVID-19 Vaccines Outweigh Risks for Those 12 and Older
After reviewing evidence, including data on risks for myocarditis, vaccination benefits outweigh risks for all populations
Omega-3 Fatty Acids Tied to Better Cardiovascular Outcomes
Cardiovascular risk reduction more prominent with EPA monotherapy versus EPA + DHA therapy
Ticagrelor, Prasugrel Compared in ACS Treated With PCI
Prespecified subgroup analysis of data from a randomized clinical trial suggest that a prasugrel-based strategy is preferable
Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease
The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.
GI Bleeding Rates With P2Y12 Platelet Inhibitors Compared
Ticagrelor and prasugrel, the newer generation of P2Y12-inhibiting antiplatelet agents, were found to be associated with fewer gastrointestinal bleeding events the first year after percutaneous coronary intervention compared with clopidogrel.
